Search Results - "Keitaro Shimozaki"

Concordance analysis of microsatellite instability status between polymerase chain reaction based testing and next generation sequencing for solid tumors by Shimozaki, Keitaro, Hayashi, Hideyuki, Tanishima, Shigeki, Horie, Sara, Chida, Akihiko, Tsugaru, Kai, Togasaki, Kazuhiro, Kawasaki, Kenta, Aimono, Eriko, Hirata, Kenro, Nishihara, Hiroshi, Kanai, Takanori, Hamamoto, Yasuo

“…Various malignancies exhibit high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). The MSI-IVD kit, a polymerase chain reaction…”
Get full text

Clinical, Endoscopic, and Pathological Characteristics of Immune Checkpoint Inhibitor-Induced Gastroenterocolitis by Hayashi, Yukie, Hosoe, Naoki, Takabayashi, Kaoru, Limpias Kamiya, Kenji J. L., Tsugaru, Kai, Shimozaki, Keitaro, Hirata, Kenro, Fukuhara, Kayoko, Fukuhara, Seiichiro, Mutaguchi, Makoto, Sujino, Tomohisa, Sukawa, Yasutaka, Hamamoto, Yasuo, Naganuma, Makoto, Takaishi, Hiromasa, Shimoda, Masayuki, Ogata, Haruhiko, Kanai, Takanori

Get full text

Current Strategy to Treat Immunogenic Gastrointestinal Cancers: Perspectives for a New Era by Shimozaki, Keitaro, Nakayama, Izuma, Hirota, Toru, Yamaguchi, Kensei

“…Since pembrolizumab, an anti-programmed death-1 (PD-1) antibody, showed a dramatic response to immunogenic cancers with microsatellite instability-high (MSI-H)…”
Get full text

KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer by Shimozaki, Keitaro, Shinozaki, Eiji, Yamamoto, Noriko, Imamura, Yu, Osumi, Hiroki, Nakayama, Izuma, Wakatsuki, Takeru, Ooki, Akira, Takahari, Daisuke, Ogura, Mariko, Chin, Keisho, Watanabe, Masayuki, Yamaguchi, Kensei

“…Purpose Although RAS and PIK3CA mutations have been associated with resistance to anti-EGFR antibody in colorectal cancer or trastuzumab in breast cancer,…”
Get full text

Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan by Aoki, Masahiko, Kadowaki, Shigenori, Takahashi, Naoki, Suzuki, Takeshi, Oshima, Kotoe, Ando, Takayuki, Yamamoto, Yoshiyuki, Kawakami, Kentaro, Kito, Yosuke, Matsumoto, Toshihiko, Shimozaki, Keitaro, Miyazaki, Yasuhiro, Yamaguchi, Toshifumi, Nagase, Michitaka, Tamura, Takao, Amanuma, Yusuke, Esaki, Taito, Miura, Yuji, Akiyoshi, Kohei, Baba, Eishi, Makiyama, Akitaka, Negoro, Yuji, Nakashima, Koji, Sugimoto, Naotoshi, Nagashima, Kengo, Shoji, Hirokazu, Boku, Narikazu

“…Background Accelerated tumor growth during immunotherapy in pre-existing measurable lesions, hyperprogressive disease (HPD), has been reported. However,…”
Get full text

Treatment efficacy of ramucirumab-containing chemotherapy in patients with alpha-fetoprotein producing gastric cancer by Kamiimabeppu, Daisaku, Wakatsuki, Takeru, Takahari, Daisuke, Fukuda, Naoki, Shimozaki, Keitaro, Osumi, Hiroki, Nakayama, Izuma, Ogura, Mariko, Ooki, Akira, Shinozaki, Eiji, Chin, Keisho, Yamaguchi, Kensei

“…Background Alpha-Fetoprotein Producing Gastric Cancer (AFPGC) is an aggressive subgroup of gastric cancer. Recently ramucirumab has shown survival benefits in…”
Get full text

Efficacy and Safety of Trastuzumab Deruxtecan and Nivolumab as Third- or Later-Line Treatment for HER2-Positive Advanced Gastric Cancer: A Single-Institution Retrospective Study by Shimozaki, Keitaro, Nakayama, Izuma, Takahari, Daisuke, Nagashima, Kengo, Yoshino, Koichiro, Fukuda, Koshiro, Fukuoka, Shota, Osumi, Hiroki, Ogura, Mariko, Wakatsuki, Takeru, Ooki, Akira, Shinozaki, Eiji, Chin, Keisho, Yamaguchi, Kensei

“…PURPOSEDetermination of optimal treatment strategies for HER2-positive advanced gastric cancer (AGC) in randomized trials is necessary despite difficulties in…”
Get full text

Ulcerative colitis exacerbation after the onset of immune checkpoint inhibitor related colitis by Kayashima, Atsuto, Shimozaki, Keitaro, Hirata, Kenro, Mutaguchi, Makoto, Takabayashi, Kaoru, Hayashi, Yuichiro, Hosoe, Naoki, Ogata, Haruhiko, Sujino, Tomohisa, Kanai, Takanori

“…Immune checkpoint inhibitors (ICPI) have been reported to be effective in various carcinomas. They excessively activate the immune system, resulting in…”
Get full text

Correlation between circulating tumor DNA and carcinoembryonic antigen levels in patients with metastatic colorectal cancer by Osumi, Hiroki, Shinozaki, Eiji, Ooki, Akira, Shimozaki, Keitaro, Kamiimabeppu, Daisaku, Nakayama, Izuma, Wakatsuki, Takeru, Ogura, Mariko, Takahari, Daisuke, Chin, Keisho, Yamaguchi, Kensei

“…Background Circulating tumor DNA (ctDNA) is a biomarker with potential to reflect comprehensive genomic information and overcome intratumor heterogeneity. In…”
Get full text

Severe drug eruption after antibiotic administration in patients receiving immune checkpoint inhibitors: A monocentric case series by Nishizawa, Aya, Takeda, Koichi, Urasaki, Tetsuya, Ono, Makiko, Mochizuki, Toshiaki, Shiga, Taro, Fujiwara, Motohiro, Yuasa, Takeshi, Murakami, Atsushi, Koike, Ryo, Yunokawa, Mayu, Kanao, Hiroyuki, Shimozaki, Keitaro, Takahari, Daisuke, Kogawa, Takahiro, Takahashi, Shunji, Kitano, Shigehisa

“…Immune checkpoint inhibitor (ICI) therapy is often associated with cutaneous immune‐related adverse events (irAEs). Drug eruptions stemming from concomitantly…”
Get full text

The Entire Intestinal Tract Surveillance Using Capsule Endoscopy after Immune Checkpoint Inhibitor Administration: A Prospective Observational Study by Shimozaki, Keitaro, Hirata, Kenro, Horie, Sara, Chida, Akihiko, Tsugaru, Kai, Hayashi, Yukie, Kawasaki, Kenta, Miyanaga, Ryoichi, Hayashi, Hideyuki, Mizuno, Ryuichi, Funakoshi, Takeru, Hosoe, Naoki, Hamamoto, Yasuo, Kanai, Takanori

“…Despite the proven efficacy of immune checkpoint inhibitors (ICIs) against various types of malignancies, they have been found to induce immune-related adverse…”
Get full text

Efficacy and Safety of Trastuzumab Deruxtecan and Nivolumab as Third- or Later-Line Treatment for HER2-Positive Advanced Gastric Cancer: A Single-Institution Retrospective Study by Keitaro Shimozaki, Izuma Nakayama, Daisuke Takahari, Kengo Nagashima, Koichiro Yoshino, Koshiro Fukuda, Shota Fukuoka, Hiroki Osumi, Mariko Ogura, Takeru Wakatsuki, Akira Ooki, Eiji Shinozaki, Keisho Chin, Kensei Yamaguchi

“…Purpose: Determination of optimal treatment strategies for HER2-positive advanced gastric cancer (AGC) in randomized trials is necessary despite difficulties…”
Get full text

A scoring system for selecting nivolumab or irinotecan in the later-line chemotherapy for advanced gastric cancer: A Japanese multicenter retrospective study by Amanuma, Yusuke, Suzuki, Takeshi, Kawakami, Takeshi, Aoki, Masahiko, Yamamoto, Yoshiyuki, Shimozaki, Keitaro, Satake, Hironaga, Nojima, Masanori, Boku, Narikazu, Takahari, Daisuke

“…266 Background: Although Nivolumab (NIVO) or Irinotecan (IRI) monotherapy is one of the later-line chemotherapies for the advanced gastric cancer (AGC)…”
Get full text

Efficacy and safety of trastuzumab deruxtecan and nivolumab as third- or later-line treatment for HER2-positive advanced gastric cancer: A single-institution retrospective study by Shimozaki, Keitaro, Nakayama, Izuma, Takahari, Daisuke, Nagashima, Kengo, Yoshino, Koichiro, Fukuda, Koshiro, Fukuoka, Shota, Osumi, Hiroki, Ogura, Mariko, Wakatsuki, Takeru, Ooki, Akira, Shinozaki, Eiji, Chin, Keisho, Yamaguchi, Kensei

“…265 Background: Despite the difficulty of directly comparing trastuzumab deruxtecan (T-DXd) and nivolumab as third- or later-line treatment for HER2-positive…”
Get full text

P57-2 Retrospective study of second-line FOLFOX versus S1 for advanced biliary tract cancer by Chida, Akihiko, Hamamoto, Yasuo, So, Eiichiro, Shimizu, Satoko, Kishimoto, Shotaro, Horie, Sara, Saito, Yuki, Shimozaki, Keitaro, Togasaki, Kazuhiro, Tsugaru, Kai, Hirata, Kenro, Hayashi, Hideyuki, Kanai, Takanori

Get full text

MO39-4 Efficacy and safety of trifluridine/tipiracil as a salvage-line treatment for patients with advanced gastric cancer by Fukuda, Koshiro, Takahari, Daisuke, Osumi, Hiroki, Nakayama, Izuma, Fukuoka, Shota, Ogura, Mariko, Ooki, Akira, Wakatsuki, Takeru, Shimozaki, Keitaro, Yoshino, Koichiro, Shinozaki, Eiji, Chin, Keisho, Yamaguchi, Kensei

Get full text

Clinical Progress in Inoperable or Recurrent Advanced Gastric Cancer Treatment from 1004 Single Institute Experiences Between 2007 and 2018 by Nakayama, Izuma, Takahari, Daisuke, Shimozaki, Keitaro, Chin, Keisho, Wakatsuki, Takeru, Ogura, Mariko, Ooki, Akira, Kamiimabeppu, Daisaku, Osumi, Hiroki, Shinozaki, Eiji, Yamaguchi, Kensei

“…In the past decade, several successful clinical trials provided new therapeutic agents approved for advanced gastric cancer (AGC). This study evaluated whether…”
Get full text

Subgroup analyses of the effect of ramucirumab in pretreatment with immune checkpoint inhibitor in RINDBeRG: A randomized clinical trial in third- or further-line treatment of gastric cancer by Kawabata, Ryohei, Sakai, Daisuke, Kadowaki, Shigenori, Tsuduki, Takao, Suzuki, Takahisa, Masuzawa, Toru, Shimozaki, Keitaro, Tsuda, Masahiro, Yamada, Takeshi, Yamaguchi, Toshifumi, Ueda, Shugo, Kito, Yosuke, Hirose, Toshiharu, Kawase, Tomono, Nomura, Takashi, Nishikawa, Kazuhiro, Kawakami, Hisato, Shimokawa, Toshio, Boku, Narikazu, Satoh, Taroh

“…339 Background: To confirm synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment, we evaluated the effect of pretreatment…”
Get full text

Pre-existing Interstitial Lung Abnormalities and Immune Checkpoint Inhibitor-Related Pneumonitis in Solid Tumors: A Retrospective Analysis by Horiuchi, Kohei, Ikemura, Shinnosuke, Sato, Takashi, Shimozaki, Keitaro, Okamori, Satoshi, Yamada, Yoshitake, Yokoyama, Yoichi, Hashimoto, Masahiro, Jinzaki, Masahiro, Hirai, Ikuko, Funakoshi, Takeru, Mizuno, Ryuichi, Oya, Mototsugu, Hirata, Kenro, Hamamoto, Yasuo, Terai, Hideki, Yasuda, Hiroyuki, Kawada, Ichiro, Soejima, Kenzo, Fukunaga, Koichi

“…Immune checkpoint inhibitors (ICIs) have demonstrated efficacy over previous cytotoxic chemotherapies in clinical trials among various tumors. Despite their…”
Get full text

Clinical impact of DNA methylation status on first-line antiepidermal growth factor receptor treatment in patients with metastatic colorectal cancer by Osumi, Hiroki, Ouchi, Kota, Shinozaki, Eiji, Takahashi, Shin, Ooki, Akira, Shimozaki, Keitaro, Nakayama, Izuma, Wakatsuki, Takeru, Ogura, Mariko, Takahari, Daisuke, Chin, Keisho, Yamaguchi, Kensei, Ishioka, Chikashi

“…3528 Background: The CpG island methylator phenotype (CIMP), important for carcinogenesis, is a predictor of prognosis and chemotherapy sensitivity in…”
Get full text